Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation

Bortezomib and TRAIL: A perfect match for apoptotic elimination of tumour cells?

(2012) L.H.A.M. de Wilt et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Bortezomib Primes Neuroblastoma Cells for TRAIL-Induced Apoptosis by Linking the Death Receptor to the Mitochondrial Pathway

(2011) I. Naumann et al.   CLINICAL CANCER RESEARCH

Bortezomib Primes Glioblastoma, Including Glioblastoma Stem Cells, for TRAIL by Increasing tBid Stability and Mitochondrial Apoptosis

(2011) T. Unterkircher et al.   CLINICAL CANCER RESEARCH

RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis

(2011) S Löder et al.   LEUKEMIA

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7

(2011) Ingrid E. Wertz et al.   NATURE

Mitosis as an anti-cancer target

(2011) A Janssen et al.   ONCOGENE

Post-transcriptional and post-translational regulation of Bcl2: Figure 1

(2010) Shaun Willimott et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition

(2010) Daisuke Tamura et al.   CANCER SCIENCE

Ubiquitylation and proteasomal degradation of the p21Cip1, p27Kip1and p57Kip2CDK inhibitors

(2010) Zhimin Lu et al.   CELL CYCLE

Phosphorylation of Mcl-1 by CDK1–cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest

(2010) Margaret E Harley et al.   EMBO JOURNAL

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

(2010) Klaus Strebhardt   NATURE REVIEWS DRUG DISCOVERY

Histone deacetylase inhibitors cooperate with IFN-γ to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8

(2009) S Häcker et al.   ONCOGENE

Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis

(2008) Ansgar Brüning et al.   INVESTIGATIONAL NEW DRUGS

The NF-κB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs

(2008) Mario I. Vega et al.   LEUKEMIA & LYMPHOMA

Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity

(2008) Valérie Combaret et al.   Molecular Cancer